Canadian Based Peptide Supplier|Ships from British Columbia, Canada|International Shipping Available|HPLC-Tested Batches|>99% Purity Specification|Same Day Shipping|Batch-Specific COAs|Canadian Based Peptide Supplier|Ships from British Columbia, Canada|International Shipping Available|HPLC-Tested Batches|>99% Purity Specification|Same Day Shipping|Batch-Specific COAs|Canadian Based Peptide Supplier|Ships from British Columbia, Canada|International Shipping Available|HPLC-Tested Batches|>99% Purity Specification|Same Day Shipping|Batch-Specific COAs|Canadian Based Peptide Supplier|Ships from British Columbia, Canada|International Shipping Available|HPLC-Tested Batches|>99% Purity Specification|Same Day Shipping|Batch-Specific COAs|
234 peptides tracked

Clinical Trials
Tracker

Visual pipeline of peptide research stages — from early preclinical studies through FDA approval. Filter by phase, search by name.

FDA Approved

(58)

Authorised by the US Food and Drug Administration for at least one human indication.

Semaglutide

A

Metabolic / GLP-1 Agonist

FDA-approved (Ozempic for T2D, Wegovy for obesity)

View Product

Tirzepatide

A

Metabolic / Dual GIP-GLP-1 Agonist

FDA-approved (Mounjaro for T2D, Zepbound for obesity and OSA)

View Product

PT-141

A

Sexual Health

FDA-approved (Vyleesi for HSDD in premenopausal women)

View Product

Tesamorelin

A

Growth Hormone Secretagogue

FDA-approved (Egrifta SV 2019, Egrifta WR March 2025) for HIV-associated lipodystrophy

View Product

Gonadorelin

A

Reproductive / Hormonal

FDA-approved (Factrel for diagnostic use; Lutrepulse for pulsatile infertility treatment, now discontinued). Generic diagnostic formulation available.

View Product

SS-31

A

Metabolic / Mitochondrial

FDA-approved (Forzinity, September 2025) for Barth syndrome. Phase II (heart failure, renal dysfunction, age-related macular degeneration).

View Product

Liraglutide

A

Metabolic / GLP-1 Agonist

FDA-approved (Victoza for T2D, Saxenda for obesity)

Exenatide

A

Metabolic / GLP-1 Agonist

FDA-approved (Byetta for T2D, 2005; Bydureon for T2D, 2012)

Dulaglutide

A

Metabolic / GLP-1 Agonist

FDA-approved (Trulicity for T2D, September 2014; cardiovascular risk reduction, 2020)

Lixisenatide

A

Metabolic / GLP-1 Agonist

FDA-approved (Adlyxin for T2D, July 2016; Soliqua 100/33 combination, November 2016)

Pramlintide

A

Metabolic / Amylin Analog

FDA-approved (Symlin for T1D and T2D as adjunct to mealtime insulin, March 2005)

Calcitonin (Salmon)

A

Metabolic / Bone Health

FDA-approved (Miacalcin injection 1986; Miacalcin nasal spray 1995; Fortical nasal spray 2005). Used for osteoporosis, Paget disease, and hypercalcemia.

Setmelanotide

A

Metabolic / MC4R Agonist

FDA-approved (Imcivree, November 2020 for POMC/PCSK1/LEPR deficiency obesity; June 2022 for BBS obesity)

Oxytocin

A

Reproductive / Hormonal

FDA-approved (Pitocin for labor induction, augmentation of labor, and postpartum hemorrhage)

View Product

Vasopressin

A

Reproductive / Hormonal

FDA-approved (Vasostrict for vasodilatory shock in adults)

Desmopressin

A

Reproductive / Hormonal

FDA-approved (DDAVP for central diabetes insipidus, hemophilia A, type 1 von Willebrand disease, primary nocturnal enuresis)

Terlipressin

A

Reproductive / Hormonal

FDA-approved (Terlivaz for hepatorenal syndrome type 1, September 2022)

Leuprolide

A

Reproductive / Hormonal

FDA-approved (Lupron Depot for prostate cancer, endometriosis, uterine fibroids, central precocious puberty; Eligard for prostate cancer; Fensolvi for central precocious puberty)

Goserelin

A

Reproductive / Hormonal

FDA-approved (Zoladex for prostate cancer, breast cancer, endometriosis, endometrial thinning)

Triptorelin

A

Reproductive / Hormonal

FDA-approved (Trelstar for advanced prostate cancer; Triptodur for central precocious puberty)

Nafarelin

A

Reproductive / Hormonal

FDA-approved (Synarel for endometriosis and central precocious puberty)

Histrelin

A

Reproductive / Hormonal

FDA-approved (Vantas for advanced prostate cancer; Supprelin LA for central precocious puberty)

Degarelix

A

Reproductive / Hormonal

FDA-approved (Firmagon for advanced prostate cancer, December 2008)

Ganirelix

A

Reproductive / Hormonal

FDA-approved (Ganirelix Acetate Injection for prevention of premature LH surges in IVF, 1999)

Cetrorelix

A

Reproductive / Hormonal

FDA-approved (Cetrotide for prevention of premature LH surges in IVF)

Macimorelin

A

Growth Hormone Secretagogue

FDA-approved (December 2017) as a diagnostic test for adult GH deficiency.

Growth Hormone

A

Hormone

FDA-approved for multiple indications. First approved in 1985 (recombinant form).

IGF-1

A

Growth Factor

FDA-approved (Increlex/mecasermin) for severe primary IGF-1 deficiency.

View Product

Angiotensin II

A

Cardiovascular / Vasoactive

FDA-approved (Giapreza, December 2017) for vasodilatory shock in adults

Nesiritide

A

Cardiovascular / Natriuretic

FDA-approved (Natrecor, August 2001) for acute decompensated heart failure. Use declined significantly after ASCEND-HF trial (2011) showed no mortality benefit.

Octreotide

A

Endocrine / Somatostatin Analog

FDA-approved (Sandostatin 1988; Sandostatin LAR 1998)

Lanreotide

A

Endocrine / Somatostatin Analog

FDA-approved (Somatuline Depot for acromegaly 2007; GEP-NETs 2014)

Pasireotide

A

Endocrine / Somatostatin Analog

FDA-approved (Signifor SC for Cushing disease, 2012; Signifor LAR for acromegaly, 2014)

Glucagon

A

Metabolic / Pancreatic Hormone

FDA-approved (emergency hypoglycemia treatment; GI diagnostic aid)

Teduglutide

A

Gastrointestinal / GLP-2 Analog

FDA-approved (Gattex for SBS, December 2012)

Plecanatide

A

Gastrointestinal / GC-C Agonist

FDA-approved (Trulance for CIC, January 2017; IBS-C, January 2018)

Linaclotide

A

Gastrointestinal / GC-C Agonist

FDA-approved (Linzess for IBS-C and CIC, August 2012)

Abaloparatide

A

Bone / PTH Analog

FDA-approved (Tymlos for postmenopausal osteoporosis, April 2017)

Teriparatide

A

Bone / PTH Analog

FDA-approved (Forteo for osteoporosis, November 2002)

Calcitonin Salmon

A

Bone / Calcitonin

FDA-approved (Miacalcin nasal spray and injection; Fortical nasal spray)

PTH (Parathyroid Hormone)

A

Bone / PTH Analog

FDA-approved (Natpara for hypoparathyroidism, 2015; voluntary recall 2019 due to device issue; returned to market)

Afamelanotide

A

Melanocortin Agonist

FDA-approved (Scenesse for EPP, October 2019); EMA-approved (2014)

Bremelanotide

A

Sexual Health

FDA-approved (Vyleesi for premenopausal HSDD, June 2019)

Difelikefalin

A

Pain / Kappa-Opioid Agonist

FDA-approved (Korsuva for CKD-associated pruritus in hemodialysis patients, August 2021)

Ziconotide

A

Pain / Calcium Channel Blocker

FDA-approved (Prialt for severe chronic pain via intrathecal infusion, December 2004)

Romiplostim

A

Hematology / TPO Agonist

FDA-approved (Nplate for chronic ITP, August 2008)

Enfuvirtide

A

Antiviral / HIV

FDA-approved (Fuzeon for HIV-1 infection in treatment-experienced patients, March 2003)

Icatibant

A

Rare Disease / Bradykinin Antagonist

FDA-approved (Firazyr for acute HAE attacks, August 2011)

Eptifibatide

A

Cardiovascular / Antiplatelet

FDA-approved (Integrilin for ACS/PCI, 1998)

Bivalirudin

A

Cardiovascular / Antithrombotic

FDA-approved (Angiomax for PCI anticoagulation, 2000)

Desirudin

A

Cardiovascular / Antithrombotic

FDA-approved (Iprivask for DVT prophylaxis post hip replacement, 2003)

HCG

A

Hormonal / Reproductive

FDA-approved for anovulation/infertility, hypogonadotropic hypogonadism, prepubertal cryptorchidism.

View Product

L-Carnitine (Injectable)

B

Metabolic / Fat Oxidation

FDA-approved (IV, for carnitine deficiency). SC injection widely used off-label for metabolic optimization.

HGH 191AA

A

Growth Hormone

FDA-approved (multiple indications). Numerous brand-name products available worldwide.

Melanotan I (Afamelanotide)

A

Dermatology / Approved

FDA-approved (2019) and EMA-approved (2014) for EPP

View Product

TRH (Thyrotropin-Releasing Hormone)

B

Neuroendocrine / Approved (diagnostic)

FDA-approved as diagnostic agent (Protirelin)

Somatropin (rHGH)

A

Growth Hormone

FDA-approved for multiple indications. Extensive clinical data spanning decades.

HMG

A

Reproductive / Hormone Support

FDA-approved (Menopur) for controlled ovarian stimulation and hypogonadotropic hypogonadism.

Approved Outside the US

(14)

Authorised by a national regulator outside the United States. Not FDA approved.

GHRP-2

C

Growth Hormone Secretagogue

Approved in Japan for GH deficiency diagnosis; research-only elsewhere

View Product

Thymosin Alpha-1

C

Immune Modulator

Approved in 35+ countries (Zadaxin); FDA orphan drug designation; not FDA-approved in the US

View Product

Selank

D

Nootropic / Anxiolytic

Approved in Russia as an anxiolytic nasal spray; not approved elsewhere

View Product

Semax

D

Nootropic / Neuroprotective

Approved in Russia and Ukraine for stroke and cognitive disorders; not approved elsewhere

View Product

Cerebrolysin

C

Nootropic / Neuroprotective

Approved as prescription drug in 50+ countries (Austria, Russia, China, South Korea, and others). Not FDA-approved. Over 150 clinical trials with >7,000 patients.

View Product

Mazdutide

C

Metabolic / Dual GLP-1/Glucagon Agonist

Approved in China: June 2025 for chronic weight management, September 2025 for type 2 diabetes. Phase 2 trials running in the United States. Not approved outside China.

View Product

Carbetocin

A

Reproductive / Hormonal

WHO Essential Medicine. Approved in over 30 countries for PPH prevention following cesarean section. Not FDA-approved in the United States.

Buserelin

A

Reproductive / Hormonal

Approved in EU, Canada, Australia, and other markets for prostate cancer, endometriosis, and IVF protocols. Not FDA-approved in the United States.

Oligopeptide-1 / EGF

C

Growth Factor / Cosmetic

Approved for wound healing in some countries (South Korea, Cuba). Used as a cosmetic ingredient globally.

Noopept

C

Nootropic / Cognitive

Approved in Russia for cognitive disorders. Not evaluated by FDA, EMA, or other Western regulatory agencies. Clinical trial data primarily in Russian-language literature.

Thymalin

C

Immune / Anti-Aging

Approved medication in Russia for immunodeficiency. Used clinically since 1982. Western clinical evidence is limited.

View Product

Thymogen

D

Immune Modulator / Bioregulator

Approved in Russia for clinical use. No Western regulatory approval. Very limited English-language evidence.

Anamorelin

B

Growth Hormone Secretagogue

Approved in Japan (2021) for cancer cachexia. Phase III trials completed (ROMANA 1 & 2). Not FDA/EMA approved.

Demoxytocin

C

Reproductive / Neurological

Approved in some countries for labor induction and lactation support. Used off-label for anxiolytic and pro-social effects.

Approval Withdrawn

(2)

Held a regulatory approval that has since been discontinued or withdrawn.

Sermorelin

C

Growth Hormone Secretagogue

Previously FDA-approved (Geref, discontinued); now used off-label via compounding

View Product

Albiglutide

A

Metabolic / GLP-1 Agonist

Previously FDA-approved (Tanzeum for T2D, April 2014). Voluntarily withdrawn from market July 2018 (commercial reasons, not safety).

Phase III

(20)

In or through Phase III human trials. Not approved.

Retatrutide

B

Metabolic / Triple Agonist

Phase 3 clinical trials (Eli Lilly TRIUMPH program)

View Product

Cagrilintide

B

Metabolic / Amylin Analog

Phase 3 (REDEFINE program). NDA filed with FDA in 2026 for CagriSema.

View Product

Survodutide

B

Metabolic / Dual Agonist

Phase 3 clinical trials for MASH and obesity (Boehringer Ingelheim)

View Product

Pemvidutide

C

Metabolic / Dual GLP-1/Glucagon Agonist

Phase II completed (MOMENTUM for obesity, IMPACT for NASH/MASH). Phase III anticipated.

Cotadutide

C

Metabolic / Dual GLP-1/Glucagon Agonist

Phase II completed for T2D, obesity, and NASH/MASH. Development status uncertain; AstraZeneca has not advanced to Phase III.

Danuglipron

B

Metabolic / Oral GLP-1 Agonist (Small Molecule)

Phase III (once-daily modified-release formulation for T2D and obesity). Pfizer discontinued the twice-daily formulation development in 2023.

Orforglipron

B

Metabolic / Oral GLP-1 Agonist (Small Molecule)

Phase III (ATTAIN trial program for T2D and obesity). Eli Lilly expects regulatory submission based on ATTAIN results.

HGH Fragment 176-191

D

Growth Hormone Fragment

Preclinical. The stabilized analog AOD-9604 completed Phase III for obesity but failed primary efficacy endpoints.

View Product

Thymosin Beta-4

B

Healing & Recovery

Multiple Phase II and Phase III clinical trials for ophthalmic indications. No full FDA approval yet.

Larazotide

B

Healing & Recovery

Phase III completed (INN-202/CeDLara trial). Awaiting further development steps.

Pexiganan

C

Antimicrobial / Immune

Phase III completed. Two NDA submissions to FDA (1999 and 2016) — both unsuccessful. Not approved in any jurisdiction.

Omiganan

C

Antimicrobial / Immune

Phase III completed for catheter infections (not approved, 2003). Phase III for rosacea (CLS001 by Cutanea Life Sciences, results ~2018). No regulatory approval.

Brilacidin

C

Antimicrobial / Immune

Phase II completed for ABSSSI (positive results). Phase II for oral mucositis. Investigated for COVID-19 (in vitro). No Phase III initiated.

VIP (Vasoactive Intestinal Peptide)

B

Neuropeptide / Reference

Aviptadil (synthetic VIP) received FDA Emergency Use Authorization consideration for COVID-19 ARDS. Phase II/III trials for ARDS completed. Not FDA-approved for any indication. Investigational for pulmonary hypertension and sarcoidosis.

View Product

Glutathione

B

Antioxidant / Detoxification

Widely used in clinical practice (IV/SC). Multiple Phase II/III trials for NAFLD, Parkinson disease, and cystic fibrosis.

View Product

AICAR

C

Metabolic / Exercise Mimetic

Phase II/III clinical trials for cardiac ischemia (acadesine). WADA-banned metabolic modulator. No FDA approval.

Enclomiphene

B

Hormonal & Reproductive

Phase III completed but FDA approval denied (2015). Available through compounding pharmacies and research suppliers.

Tesofensine

C

Weight Loss / Reuptake Inhibitor

Phase 3 clinical trials (Saniona). Phase 2 completed with significant weight loss results.

Amycretin

C

Weight Loss / GLP-1 Agonist

Phase 2 completed (REDEFINE 1). Phase 3 expected 2026. Investigational — not approved anywhere.

Human Relaxin-2

C

Cardiovascular

Phase 3 completed (RELAX-AHF-2 failed primary endpoint). Development halted by Novartis. Research continues in fibrosis indications.

Phase II

(16)

In or through Phase II human trials. Not approved.

BPC-157

C

Healing & Recovery

Research-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway.

View Product

AOD-9604

C

Metabolic / Fat Loss

Clinical development discontinued after Phase 2; GRAS status for food use

View Product

MK-677

C

Growth Hormone Secretagogue

Multiple Phase II trials completed. Not FDA-approved. Investigational.

Hexarelin

C

Growth Hormone Secretagogue

Phase II completed. Development discontinued due to tolerance/desensitization concerns.

View Product

ARA-290 (Cibinetide)

C

Tissue Repair / Neuropathic Pain

Phase II clinical trials completed for sarcoidosis neuropathy, diabetic neuropathy, and corneal nerve repair. FDA Orphan Drug Designation granted. Not yet approved.

View Product

Follistatin 344

D

Growth Factor

Gene therapy (AAV1-FS344): Phase I/II trials completed for Becker muscular dystrophy (Mendell et al., Mol Ther 2015) and inclusion body myositis (Mendell et al., Mol Ther 2017). Recombinant protein: no human clinical trials.

NAD+ (Nicotinamide Adenine Dinucleotide)

C

Anti-Aging / Telomere

NAD+ IV: used clinically at anti-aging and addiction clinics; no FDA approval. NMN: Phase I/II human trials completed (Yoshino et al., Science 2021). NR: multiple human trials completed.

View Product

Tabimorelin

C

Growth Hormone Secretagogue

Phase II completed. Development discontinued.

IM862

D

Immune Modulator

Development discontinued. Phase II for AIDS-related Kaposi sarcoma failed to show efficacy (2002). No further clinical development.

PACAP

D

Neuropeptide / Reference

Endogenous neuropeptide under active investigation. PACAP/PAC1 pathway is a validated migraine target (anti-PACAP antibody AMG 301/Lu AG09222 in Phase II). Investigated in PTSD, neurodegenerative diseases, and traumatic brain injury.

ACE-031

C

Muscle Growth / Research

Phase I/II completed (DMD). Development discontinued by Acceleron Pharma (2013) due to vascular adverse events. Successor programs (ACE-083, local) also discontinued.

View Product

Eloralintide

C

Weight Loss & Metabolic

Phase II clinical trials by Eli Lilly. Active development as of 2025.

View Product

Kisspeptin-10

B

Hormonal & Reproductive

Phase II clinical trials for reproductive disorders. Active academic research programs.

View Product

CJC-1295 with DAC

C

Growth Hormone

Research compound. Phase 1/2 clinical data exists (ConjuChem). Not approved for any indication.

View Product

Myostatin Propeptide

D

Muscle Growth

Preclinical research. No human clinical trials for the propeptide form specifically. Related approaches (anti-myostatin antibodies) in Phase 2-3.

Trevogrumab

C

Muscle Growth / Monoclonal Antibody

Phase 2-3 clinical trials. Being studied in TOPAZ program for inclusion body myositis (with garetosmab).

Phase I

(1)

In or through Phase I human trials. Not approved.

MOTS-c

D

Metabolic / Mitochondrial

Research-only / No human clinical trials completed (Phase 1 of analog CB4211 only)

View Product

Preclinical / Research

(123)

No approved human indication. Evidence is preclinical, observational or absent.

TB-500

D

Healing & Recovery

Research-only / Veterinary use in some jurisdictions. Limited human RCTs completed.

View Product

Ipamorelin

D

Growth Hormone Secretagogue

Research-only / Not approved for human use

View Product

CJC-1295

D

Growth Hormone Secretagogue

Research-only / Not approved for human use

View Product

GHK-Cu

F

Skin & Tissue Repair

Available in cosmetic formulations; no drug approval

View Product

Melanotan II

F

Melanocortin Agonist

Research-only / Not approved. Multiple regulatory warnings issued worldwide.

View Product

LL-37

D

Antimicrobial / Immune

Investigational / Limited clinical trial data (topical wound healing RCT exists)

View Product

GHRP-6

D

Growth Hormone Secretagogue

Research-only / Not approved for human use

View Product

Epithalon

D

Anti-Aging / Telomere

Research-only / No approved human indication in Western countries

View Product

Dihexa

F

Nootropic / Cognitive

Research-only / Preclinical. CAUTION: foundational paper retracted April 2025 for data fabrication.

View Product

DSIP

D

Sleep / Neuropeptide

Research-only / Not approved for any indication

View Product

Kisspeptin

C

Reproductive / Hormonal

Investigational / Active clinical trials in reproductive medicine

View Product

KPV

D

Anti-Inflammatory / Immune

Preclinical. No formal clinical trials completed. Used in compounding pharmacy protocols. Removed from FDA Category 2 on April 15, 2026.

View Product

IGF-1 LR3

D

Growth Factor

No clinical trials for therapeutic use. Research compound only.

View Product

FOXO4-DRI

D

Senolytic / Anti-Aging

Preclinical. No human clinical trials. Animal studies in aged mice (Baar et al., Cell 2017).

View Product

Humanin

D

Metabolic / Mitochondrial

Preclinical. No completed clinical trials. Epidemiological studies show correlation with longevity.

View Product

Argireline

F

Cosmetic / Anti-Wrinkle

Commercially available as cosmetic ingredient. Not a pharmaceutical.

PEG-MGF

D

Muscle & Performance

Research-only. No human clinical trials registered or completed. Preclinical characterization primarily in cell culture and rodent models.

View Product

5-Amino-1MQ

D

Metabolic / Fat Loss

Preclinical only. No IND filed. No human clinical trials registered as of 2026.

View Product

Amylin

B

Metabolic / Endogenous Hormone

Endogenous hormone. Not itself used as a drug. Serves as the basis for pramlintide (Symlin, FDA-approved) and cagrilintide (investigational).

Alexamorelin

D

Growth Hormone Secretagogue

Preclinical only. No clinical trials registered or completed.

MGF

D

Growth Factor

Preclinical only. No human clinical trials.

View Product

IGF-1 DES

D

Growth Factor

Preclinical only. No human clinical trials.

Collagen Peptides

F

Healing & Recovery

Dietary supplement with multiple published RCTs. Not a pharmaceutical product.

Matrixyl

F

Cosmetic Peptide

Cosmetic ingredient. No pharmaceutical regulatory approval. Limited clinical studies.

Matrixyl 3000

F

Cosmetic Peptide

Cosmetic ingredient. Limited published clinical data.

Snap-8

F

Cosmetic Peptide

Cosmetic ingredient. Manufacturer studies only; no independent clinical trials.

View Product

Palmitoyl Tripeptide-1

F

Cosmetic Peptide

Cosmetic ingredient. Very limited independent clinical data.

Palmitoyl Tetrapeptide-7

F

Cosmetic Peptide

Cosmetic ingredient. Minimal independent clinical data.

Palmitoyl Tripeptide-5

F

Cosmetic Peptide

Cosmetic ingredient. Manufacturer data only; no independent clinical trials.

Copper Tripeptide-1

F

Cosmetic Peptide

Cosmetic ingredient with clinical studies. Also studied for wound healing.

Acetyl Tetrapeptide-5

F

Cosmetic Peptide

Cosmetic ingredient. Manufacturer studies only.

Tripeptide-29

F

Cosmetic Peptide

Cosmetic ingredient. Very limited clinical data for topical use.

Myristoyl Pentapeptide-17

F

Cosmetic Peptide

Cosmetic ingredient. Very limited published clinical data.

Biotinoyl Tripeptide-1

F

Cosmetic Peptide

Cosmetic ingredient. Limited published data, mostly as part of Procapil complex.

Sh-Polypeptide-1

F

Cosmetic Peptide

Cosmetic ingredient. Clinical data draws on general EGF research rather than studies specific to this INCI name.

Thymulin

C

Immune Modulator

Investigational. Small clinical studies in immunodeficiency and aging; no approved therapeutic indication.

Beta-Defensins

D

Antimicrobial / Immune

Endogenous peptides. No therapeutic product in clinical development. Studied as biomarkers and templates for antimicrobial drug design.

Alpha-Defensins

D

Antimicrobial / Immune

Endogenous peptides. No therapeutic product in clinical development. Studied as biomarkers (e.g., synovial fluid alpha-defensin test for periprosthetic joint infection).

Lactoferricin

D

Antimicrobial / Immune

Preclinical research only. No clinical trials registered for lactoferricin as a standalone therapeutic.

Melittin

D

Antimicrobial / Immune

Preclinical. Bee venom therapy (apitherapy) is used in traditional medicine. No approved pharmaceutical product based on isolated melittin.

Histatin-5

D

Antimicrobial / Immune

Endogenous peptide. No therapeutic product in development. Studied as a template for antifungal drug design.

Pinealon

D

Nootropic / Neuroprotective

Preclinical / small open-label Russian studies only. No controlled clinical trials. Sold as a dietary supplement in Russia.

View Product

Cortagen

D

Nootropic / Neuroprotective

Preclinical / small open-label Russian studies only. No controlled clinical trials. Available as a dietary supplement in Russia.

View Product

N-Acetyl Semax Amidate

D

Nootropic / Neuroprotective

Research chemical only. No published clinical trials. No regulatory evaluation. All pharmacological claims are extrapolated from Semax data.

PE-22-28

D

Nootropic / Neuroprotective

Preclinical tool compound only. No clinical trials. No regulatory evaluation.

View Product

Substance P

B

Neuropeptide / Reference

Endogenous neuropeptide. Not a drug. NK1R antagonists (aprepitant, fosaprepitant, netupitant) are FDA-approved antiemetics. NK1R antagonists for depression showed mixed clinical results.

Neuropeptide Y

B

Neuropeptide / Reference

Endogenous neuropeptide. Not a drug. NPY receptor agonists and antagonists have been investigated for obesity, anxiety, and epilepsy but none are approved.

Angiotensin 1-7

D

Cardiovascular / Vasoactive

Preclinical and early-phase research. No approved therapeutic indication.

Bradykinin

B

Cardiovascular / Vasoactive

Reference peptide. Not used therapeutically. Clinically relevant as mediator of ACE inhibitor side effects and hereditary angioedema.

Atrial Natriuretic Peptide

B

Cardiovascular / Natriuretic

Carperitide (recombinant hANP) approved in Japan (1995) for acute heart failure. Not approved in the US, EU, or other Western markets.

B-type Natriuretic Peptide

B

Cardiovascular / Natriuretic

Established diagnostic biomarker for heart failure. Recombinant form (nesiritide) is FDA-approved for acute decompensated heart failure.

Endothelin-1

B

Cardiovascular / Vasoactive

Reference peptide. Not used therapeutically. Endothelin receptor antagonists (bosentan, ambrisentan, macitentan) are FDA-approved for pulmonary arterial hypertension.

Apelin

D

Cardiovascular / Vasoactive

Preclinical and early-phase clinical investigation. No approved therapeutic indication.

Adrenomedullin

D

Cardiovascular / Vasoactive

Research stage. MR-proADM used as prognostic biomarker in sepsis and heart failure. No approved therapeutic use of adrenomedullin peptide.

Somatostatin

B

Endocrine / Somatostatin Analog

Limited clinical use (IV infusion only); synthetic analogs preferred for therapeutic applications

Adamax

D

Cognitive / Nootropic

No clinical trials. Research chemical based on Semax structure.

View Product

Adipotide

D

Experimental Fat Loss

Clinical development discontinued. Preclinical only (primate proof-of-concept). No human trials conducted.

View Product

PNC-27

D

Cancer Research

No human clinical trials. In vitro cell culture studies only. FDA has issued explicit warnings against PNC-27 products.

SLU-PP-332

D

Experimental Exercise Mimetic

Preclinical only. Published murine studies from Washington University. No human trials planned or initiated.

View Product

Neuroxelin

D

Cognitive / Neuroprotection

No clinical trials. No substantial peer-reviewed publications. Vendor/manufacturer claims only.

Vilon

D

Immune / Anti-Aging

Published in Russian biogerontology literature. Limited peer review in English-language journals.

Livagen

D

Hepatic / Anti-Aging

Published in Russian biogerontology literature. Limited Western peer review.

Bronchogen

D

Respiratory / Anti-Aging

Russian clinical studies in elderly patients with chronic bronchitis. Limited peer review.

Cardiogen

D

Cardiovascular / Anti-Aging

Russian clinical studies in elderly patients with cardiovascular disease. Not validated in Western trials.

View Product

Pancragen

D

Metabolic / Anti-Aging

Russian clinical studies in patients with metabolic syndrome and type 2 diabetes. Not validated in Western trials.

Vesilute

D

Cardiovascular / Anti-Aging

Russian clinical studies in elderly patients with vascular disease. Not validated in Western trials.

Testagen

D

Hormonal / Anti-Aging

Russian clinical studies in elderly men. Not validated in Western trials.

Prostamax

D

Hormonal / Anti-Aging

Russian clinical studies in elderly men with BPH. Not validated in Western trials.

Chonluten

D

Respiratory / Anti-Aging

Russian clinical studies. Not validated in Western trials.

Tat-Beclin 1

D

Anti-Aging / Autophagy

Preclinical. Published in top journals (Nature, Cell) but no human clinical trials.

AHK (Ala-His-Lys)

D

Cosmetic / Research

Research-only

View Product

AHK-Cu (Copper AHK)

D

Cosmetic / Research

Research-only

View Product

B7-33

D

Cardiovascular / Research

Preclinical research

Cartalax

D

Bioregulator / Research

Research-only

Decapeptide-12

D

Cosmetic

Cosmetic ingredient

FGL(S)

D

Neuroprotection / Research

Research-only

Follistatin-315

D

Muscle Growth / Research

Research-only

GHK (Glycyl-Histidyl-Lysine)

C

Regenerative / Research

Research compound / Cosmetic ingredient

Melanostatin-DM (Nonapeptide-2)

D

Cosmetic

Cosmetic ingredient

N-Acetyl Epithalon Amidate

D

Anti-Aging / Research

Research-only

N-Acetyl Selank Amidate

C

Nootropic / Anxiolytic

Research-only (base form approved in Russia)

Nonapeptide-1

D

Cosmetic

Cosmetic ingredient

OS-01 (OneSkin Peptide)

D

Anti-Aging / Cosmetic

Cosmetic product (OneSkin)

Ovagen

D

Bioregulator / Research

Research-only

Pentapeptide-18 (Leuphasyl)

D

Cosmetic

Cosmetic ingredient

Rigin (Palmitoyl Tetrapeptide-7)

D

Cosmetic

Cosmetic ingredient

SYN-AKE

D

Cosmetic

Cosmetic ingredient

SYN-COLL (Palmitoyl Tripeptide-5)

D

Cosmetic

Cosmetic ingredient

TB-500 Fragment 17-23

D

Healing / Research

Research-only

Thymagen

D

Immune / Bioregulator

Research-only (approved in Russia)

Vesugen

D

Cardiovascular / Bioregulator

Research-only

View Product

Vialox (Pentapeptide-3)

D

Cosmetic

Cosmetic ingredient

Pal-GHK (Palmitoyl Tripeptide-1)

D

Cosmetic

Cosmetic ingredient

Dermorphin

D

Pain & Analgesia

Research compound only. No approved human indication. Banned in competitive horse racing.

Follistatin

C

Growth & Performance

Preclinical and early clinical gene therapy trials for muscular dystrophies. Research compound for performance applications.

FOXO4-DRI

D

Anti-Aging & Longevity

Preclinical only. Single landmark mouse study (Baar et al., Cell 2017). No human clinical trials.

GHK

C

Skin & Cosmetic

Research compound. GHK-Cu has more extensive research history. Cosmetic ingredient.

View Product

Pal-AHK

D

Skin & Cosmetic

Cosmetic ingredient. Limited clinical data for hair growth.

Palmitoyl Dipeptide-6

D

Skin & Cosmetic

Cosmetic ingredient. In vitro and small clinical cosmetic studies.

PGPIPN

D

Immune & Anti-inflammatory

Preclinical research. Limited published studies.

DS-5

F

Research & Emerging

Early research stage. No clinical trials registered.

BPC-157 + TB-500

D

Healing & Recovery

Preclinical

CAGRILINTIDE + SEMAGLUTIDE

D

Weight Loss & Metabolic

Preclinical

PTD-DBM

D

Hair Growth

Preclinical only. No human clinical trials initiated as of 2025.

Acetyl Tetrapeptide-3

D

Hair Growth / Cosmetic

Marketed as a cosmetic ingredient. Manufacturer-sponsored clinical studies only; no independent peer-reviewed RCTs.

GDF-11

D

Anti-Aging / Regenerative

Preclinical only. No human clinical trials. Highly controversial preclinical results.

P21

D

Nootropic / Neurogenesis

Preclinical only. No human clinical trials. Studied in Alzheimer's mouse models.

Cholecystokinin (CCK)

B

Satiety / Gut-Brain Axis

Well-characterized endogenous hormone. CCK-based drugs have not succeeded clinically for obesity due to tachyphylaxis.

Neuromedin U

D

Metabolic / Appetite

Preclinical. No human clinical trials for NMU itself. Long-acting NMU analogs are in early development.

Peptide YY (PYY)

B

Satiety / Metabolic

Well-characterized endogenous hormone. Infusion studies in humans completed. No approved PYY-based drug.

Uroguanylin

D

GI / Metabolic

Preclinical as a therapeutic. GC-C agonist drugs (linaclotide, plecanatide) are FDA-approved for IBS-C and chronic constipation.

CGRP

A

Pain / Migraine

Endogenous peptide. Anti-CGRP therapies are FDA-approved for migraine prevention and treatment. CGRP itself is not a therapeutic.

Cerluten

F

Bioregulator / CNS

No clinical trials registered in international databases. Available as a dietary supplement in Russia.

Kristagen

F

Bioregulator / Immune

No clinical trials in international registries. Available as a dietary supplement in Russia.

9-Me-BC

D

Nootropic / Dopaminergic

Preclinical only. No human clinical trials. In vitro and rodent data only.

Astressin-B

D

Stress / CRF Antagonist

Preclinical only. No human clinical trials. Multiple CRF1-selective antagonists have failed in clinical trials for depression and anxiety.

Zhenoluten

F

Bioregulator / Reproductive

No clinical trials in international registries. Available as a dietary supplement in Russia.

Cortexin

D

Neuroprotection / Nootropic

Registered pharmaceutical in Russia/CIS since 1999. Extensive clinical use in Russian neurology. No Western regulatory approval or clinical trials meeting international standards.

Ghrelin

B

Growth Hormone / Appetite

Endogenous hormone. Analog anamorelin approved in Japan for cancer cachexia. Multiple analogs in clinical trials.

GLP-1

A

Metabolic / Weight Loss

Endogenous hormone. Multiple analogs FDA-approved: semaglutide, liraglutide, exenatide, dulaglutide, tirzepatide (dual GIP/GLP-1).

Prostatilen

C

Bioregulator / Urological

Registered pharmaceutical preparation in Russia and Eastern Europe. Not studied in Western clinical trials.

Retinalamin

C

Bioregulator / Ophthalmic

Registered pharmaceutical in Russia. 10+ peer-reviewed clinical studies. No Western clinical trials.

BAM-15

D

Weight Loss / Metabolic

Preclinical only. No human clinical trials as of 2025.

Research Disclaimer: This tracker aggregates publicly available clinical trial status information for educational purposes only. It does not constitute medical advice. All products sold by Volta Peptides are for in vitro research use only. Clinical status data may not reflect the most recent regulatory changes.

Your Cart

Your cart is empty

Browse our catalog to add research compounds.